Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui") is a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. We have focused our R&D efforts on oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Hengrui has been on Pharma Exec’s annual listing of the global Top 50 pharmaceutical companies for six consecutive years since 2019. Hengrui ranked 8th on the list of "Top 25 Global Pharma Companies by Pipeline Size" published by Citeline in 2024.

Innovation is the core of Hengrui’s development strategy. Hengrui has spent more than US$6.35 billion (RMB46 billion) on R&D in recent years. We have built a large-scale, professional, and comprehensive innovative R&D team of more than 5,500 people. Fourteen R&D centers have been established around the world along with several subsidiaries in the U.S., Europe, Australia, and Japan. Hengrui currently has 23 commercialized new molecular entity drugs and 4 other innovative drugs. As of December 31, 2024, we were conducting approximately 400 clinical trials for more than 90 innovative drug candidates. As of December 31, 2024, we filed 2,609 patent applications in the Greater China region. As of the same date, we owned 1,084 issued patents in the Greater China region and 753 issued patents in other jurisdictions, including the U.S., Europe, and Japan.

Globalization is also an important development strategy of Hengrui. By the end of 2024, Hengrui’s products had been commercialized in more than 40 countries, and will continue to accelerate global market development, focusing on emerging markets. Hengrui has established manufacturing facilities across China. All of our exported products meet or exceed global quality standards, including the EU GMP, the U.S. cGMP, and the ICH Quality Guidelines. we had initiated over 20 overseas clinical trials,including in the U.S., Europe, Australia, Japan, and South Korea. Through our international partners, Hengrui has obtained more than 20 registration approvals including injections, oral preparations and inhalation anesthetics in the Europe, U.S. and Japan to benefit more patients around the world. We actively facilitate the transformation of our R&D findings through international collaborations, resulting in 14 out-licensing transactions for our innovative drugs and drug candidates with global partners since 2018. These include our out-licensing to a fully owned subsidiary of Merck KGaA, Darmstadt, Germany, for which the potential payments may total up to €1.4 billion, and an out-licensing deal worth approximately US$6 billion with the U.S.-based Kailera Therapeutics ("Kailera") for our GLP-1 product portfolio comprised of HRS-7535, HRS9531, and HRS-4729, in which we acquired 19.9% of the company’s shares.

Hengrui will continue its engagement in the innovation and development of treatments for various diseases spanning oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, neuroscience, and other therapeutic areas to benefit patients globally.